Paper8558199
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T and 24 others. J Clin Oncol, 1996. Cited by 90 papers, by iCite.
Cite this record
ConductScience Library. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. Papers, record 8558199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8558199
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics25
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Leukemia, Myeloid | Major topic |
| Acute Disease | |
| Adolescent | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Chi-Square Distribution | |
| Cytarabine | |
| Daunorubicin | |
| Disease-Free Survival | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Leucine | |
| Logistic Models | |
| Male | |
| Mercaptopurine | |
| Middle Aged | |
| Multivariate Analysis | |
| Prednisolone | |
| Prospective Studies | |
| Remission Induction | |
| Survival Rate | |
| Treatment Outcome |
Source PubMed
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 90 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38519889 | CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro. | BMC Cancer | 2024 | https://conductscience.org/library/papers/38519889 | PubMed |
| 29984744 | Very Late Relapse of Acute Promyelocytic Leukemia 17 Years after Continuous Remission. | Intern Med | 2018 | https://conductscience.org/library/papers/29984744 | PubMed |
| 29860713 | Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. | Support Care Cancer | 2018 | https://conductscience.org/library/papers/29860713 | PubMed |
| 29043232 | Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia. | Blood Res | 2017 | https://conductscience.org/library/papers/29043232 | PubMed |
| 27354720 | Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. | Blood | 2016 | https://conductscience.org/library/papers/27354720 | PubMed |
| 26829896 | Improving nucleoside analogs via lipid conjugation: Is fatter any better? | Crit Rev Oncol Hematol | 2016 | https://conductscience.org/library/papers/26829896 | PubMed |
| 26375984 | Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis. | PLoS One | 2015 | https://conductscience.org/library/papers/26375984 | PubMed |
| 25609058 | DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25609058 | PubMed |
| 23135354 | Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. | Leukemia | 2013 | https://conductscience.org/library/papers/23135354 | PubMed |
| 22851055 | Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. | Int J Hematol | 2012 | https://conductscience.org/library/papers/22851055 | PubMed |
| 22639053 | Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. | Int J Hematol | 2012 | https://conductscience.org/library/papers/22639053 | PubMed |
| 22220252 | Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia. | Mediterr J Hematol Infect Dis | 2011 | https://conductscience.org/library/papers/22220252 | PubMed |
| 21606963 | Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. | Leukemia | 2011 | https://conductscience.org/library/papers/21606963 | PubMed |
| 21213127 | Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. | Int J Hematol | 2011 | https://conductscience.org/library/papers/21213127 | PubMed |
| 20697159 | CD13 is a therapeutic target in human liver cancer stem cells. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20697159 | PubMed |
| 20063133 | Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. | Int J Hematol | 2010 | https://conductscience.org/library/papers/20063133 | PubMed |
| 20054669 | Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. | Int J Hematol | 2010 | https://conductscience.org/library/papers/20054669 | PubMed |
| 20052341 | Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea. | J Korean Med Sci | 2010 | https://conductscience.org/library/papers/20052341 | PubMed |
| 18055342 | Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). | Int J Hematol | 2007 | https://conductscience.org/library/papers/18055342 | PubMed |
| 15902284 | Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). | Leukemia | 2005 | https://conductscience.org/library/papers/15902284 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8558199
GET https://conductscience.org/api/papers/v1/8558199/authors?page=2